Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357612 · ClinicalTrials.gov registry record · Phase 4
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
A Phase 4 study of Parkinson Disease and Neurodegenerative Diseases, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05357612: Recruiting Phase 4 study of Parkinson Disease and Neurodegenerative Diseases, sponsored by Vanderbilt University Medical Center.
NCT05357612 is a Phase 4 study of Parkinson Disease and Neurodegenerative Diseases that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357612, a Phase 4 study of Parkinson Disease and Neurodegenerative Diseases, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Primary Outcome
Receptor density (Bmax) of 5HT2A receptors measured using the PET radioligand MH.MZ uptake in regions of interest.
Conditions Studied
Interventions
- DRUG Pimavanserin
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What NCT05357612 shows while recruiting
NCT05357612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Pimavanserin is the first listed.
NCT05357612 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05357612 about?
NCT05357612 is a clinical study titled "Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases". It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18...
What is the current status of trial NCT05357612?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2023-01-23. Estimated completion is 2026-08.
What conditions does trial NCT05357612 study?
This clinical trial studies the following conditions: Parkinson Disease, Neurodegenerative Diseases, Parkinson Disease Psychosis.
What interventions are being tested in trial NCT05357612?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT05357612?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357612 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357612's enrollment target sits among peer trials
75 112th of 297 higher than 183 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
RECRUITING · Phase 4
-
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
RECRUITING · Phase 4
-
Personalized Real-Time DBS and PD Mechanisms
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI